Jefferies raised the firm’s price target on Neurocrine (NBIX) to $169 from $160 and keeps a Buy rating on the shares. The full data from osavampator’s Phase 2 SAVITRI trial in major depressive disorder patients with inadequate response to oral antidepressant show comparable efficacy to esketamine’s Phase 3, the analyst tells investors in a research note. The firm continues to view view osavampator as a potential upside for Neurocrine shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine announces Phase 2 SAVITRI met primary efficacy endpoint
- Neurocrine’s Osavampator Shows Promising Phase 2 Results, Boosting Buy Rating and Stock Price Target
- Promising Potential of Neurocrine’s Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman
- Neurocrine price target raised to $149 from $144 at RBC Capital
- Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating